Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors
| Autor: | Akiko Fujii, Shinya Sakata, Keita Nakatomi, Yoichi Nakanishi, Ryo Toyozawa, Koji Inoue, Noriko Hidaka, Kazuko Sakai, Isamu Okamoto, Keiichi Ota, Junji Kishimoto, Taishi Harada, Eiji Iwama, Kazuto Nishio, Junko Hisasue, Takayuki Shimose, Koichi Azuma, Noriaki Nakagaki |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Cancer Research Somatic cell medicine.drug_class medicine.medical_treatment Tyrosine-kinase inhibitor Targeted therapy 03 medical and health sciences T790M 0302 clinical medicine Carcinoma Non-Small-Cell Lung medicine Humans Digital polymerase chain reaction Molecular Targeted Therapy 030212 general & internal medicine Epidermal growth factor receptor Liquid biopsy Protein Kinase Inhibitors Aged biology business.industry Hazard ratio Liquid Biopsy High-Throughput Nucleotide Sequencing Middle Aged Neoplastic Cells Circulating respiratory tract diseases ErbB Receptors Oncology Drug Resistance Neoplasm 030220 oncology & carcinogenesis Mutation Cancer research biology.protein Female business Cell-Free Nucleic Acids |
| Zdroj: | Cancer. 126:219-227 |
| ISSN: | 1097-0142 0008-543X |
| Popis: | BACKGROUND The aim of this study was to evaluate the potential of liquid biopsy for prediction of the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment and for assessment of the changes in genetic alterations during such treatment. METHODS Plasma samples were prospectively collected from non-small cell lung cancer patients with EGFR-activating mutations during EGFR-TKI treatment until disease progression and were analyzed for such mutations with droplet digital polymerase chain reaction and for other somatic alterations with next-generation sequencing. RESULTS One hundred patients, including 87 who were EGFR-TKI naive, were enrolled. Median progression-free survival was significantly shorter for EGFR-TKI-naive patients with EGFR-activating mutations detected in plasma at baseline than for those without them (7.9 vs 19.0 months; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text